VRNA实时信号 | 通过Getagraph.com最大化利润

购买 107708 min ago

@ $17.52

发出时间: 15 Feb 2024 @ 04:40

回报率: -10.10%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 1.15 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:48):

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs...

Stats
今日成交量	95 798.00
平均成交量	442 519
市值	1.22B
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.87
ATR14	$0.0150 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Fisher Andrew	Buy	2 400 000	Share Options (Right to Buy)
2024-03-04	Fisher Andrew	Buy	0
2024-02-01	Zaccardelli David	Sell	480 200	Ordinary Shares
2024-02-01	Rickard Kathleen A.	Sell	72 768	Ordinary Shares
2024-02-05	Rickard Kathleen A.	Sell	36 248	Ordinary Shares

INSIDER POWER
-13.33
Last 97 transactions
Buy: 7 137 944 \| Sell: 12 997 482

音量相关性

長: -0.37 (neutral)

短: 0.28 (neutral)

Signal:(39.833) Neutral

Verona Pharma plc 相关性

10 最正相关
SIOX	0.953
BWEN	0.952
ECHO	0.952
MLVF	0.951
IIN	0.95
AMYT	0.947
EXAS	0.943
NWLI	0.939
CDZI	0.936
EEFT	0.93

10 最负相关
PCRX	-0.936
SNPX	-0.935
KPTI	-0.93
HMNF	-0.93
LARK	-0.927
UTME	-0.926
SGLB	-0.918
OP	-0.909
BCAB	-0.909
VNDA	-0.909

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Verona Pharma plc 相关性 - 货币/商品

0.86
( strong )

0.88
( strong )

0.00
( neutral )

0.79
( moderate )

0.53
( weak )

-0.66
( moderate negative )

Verona Pharma plc 财务报表

Annual	2023
营收:	$0
毛利润:	$-679 624 (0.00 %)
EPS:	$-0.690

FY	2023
营收:	$0
毛利润:	$-679 624 (0.00 %)
EPS:	$-0.690

FY	2022
营收:	$458 000
毛利润:	$112 000 (24.45 %)
EPS:	$-1.040

FY	2021
营收:	$40.00M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.960

Financial Reports:

No articles found.

Verona Pharma plc

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.